sulfonylurea

(redirected from Sulphonylurea)
Also found in: Dictionary, Thesaurus, Wikipedia.

sulfonylurea

 [sul″fo-nil-u´re-ah]
any of a class of compounds that exert hypoglycemic activity by stimulating the islet tissue to secrete insulin; used to control hyperglycemia in patients with type 2 diabetes mellitus who cannot be treated solely by diet and exercise. The class includes the oral hypoglycemic agentsacetohexamide, chlorpropamide, glipizide, tolazamide, and tolbutamide.

sulfonylurea

/sul·fo·nyl·urea/ (sul″fŏ-nil-u-re´ah) any of a class of compounds that exert hypoglycemic activity by stimulating the islet tissue to secrete insulin; used to control hyperglycemia in patients with type 2 diabetes mellitus who cannot be treated solely by diet and exercise.

sulfonylurea

(sŭl′fə-nĭl-yo͝o-rē′ə)
n.
Any of a group of hypoglycemic drugs, such as glyburide, that act on the beta cells of the pancreas to increase the secretion of insulin and are used in the treatment of type 2 diabetes.

sulfonylurea

[sul′fənilyoo͡r′ē·ə]
an oral antidiabetic agent that stimulates the pancreatic production of insulin. Hypersensitivity to sulfonamides is a contraindication for using such agents, and ethanol consumption is incompatible with all sulfonylureas. These agents cross the placenta, and their use has been associated with a higher incidence of birth defects, making insulin the preferred drug in treating diabetes in pregnancy. Aspirin or other salicylates taken with any sulfonylurea may intensify the hypoglycemic effect.

sulfonylurea

a class of chemical compounds that includes the oral hypoglycemic agents acetohexamide, chlorpropamide, tolazamide and tolbutamide.
References in periodicals archive ?
Of these 70% had hypoglycaemia with sulphonylureas.
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
In contrast, few studies demonstrated that sulphonylurea was the commonly prescribed antidiabetic drug41, followed by combination of sulphonylurea and metformin, and metformin alone24-27.
This finding suggests a therapeutic advantage of agents targeting FFAR1, compared with sulphonylureas, which are associated with frequent occurrence of hypoglycemia.
UKPDS Group, Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: Initial response to oral sulphonylurea therapy.
The Japanese Ministry of Health, Labour and Welfare has approved the product as monotherapy of type 2 diabetes or as add-on therapy to sulphonylurea.
Onglyza is indicated as a once-daily 5 mg tablet in adult patients with type 2 diabetes to improve glycemic control in combination with metformin, sulphonylurea or thiazo-lidinedione, when these drugs alone, with diet and exercise, do not provide adequate glycaemic control.
However, most of the time people with diabetes who inject insulin or consume oral pills like sulphonylurea are at greater risk of developing hypoglycaemia.
The indications for use are improvement of glycaemic control in patients who are taking Metformin, Sulphonylurea or a combination of both.
In contrast, the sulphonylurea receptor (SUR) subunit has a binding site for adenosine di phosphate (ADP) which activates the channel.